Comments
In a blow to Mumbai-headquartered Lupin, global pharma company Mylan has launched Fenofibrate capsules to tackle coronary heart disease in the US. The capsules are the generic equivalent to Lupin's anti-cholesterol drug Antara, one of its key US brands.
It is estimated that the drug contributed $43 million to Lupin’s FY12 topline. Being a branded drug, the product contributed around 40 per cent to PAT margin.
After acquiring the brand in 2009, Lupin sold the abbreviated new drug application (ANDA) on Antara to Dr Reddy’s, which was the first to file. Other filers include Apotex, Ranbaxy and Paddock. The substance patent on Antara is set to expire in 2020.
The United States Food and Drug Administration (FDA) granted final approval to Mylan's generic version of Antara on January 10. Lupin had tried to delay the launch through an appeal in the Federal Court that granted an injunction over the district court ruling.
Analysts said Mylan has launched the product at risk.
“Given the generic launch of the product, we estimate a loss of $18-20 million, which is 1 per cent of FY14 sales and 2 per cent of FY14 PBT for Lupin,'' said Manoj Garg of Edelweiss Securities.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.